NCT07012031 2026-03-19
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
National Cancer Institute (NCI)
Phase 1/2 Recruiting
Clinical Trials
6 trialsNCT03600883 2026-03-16
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Amgen
Phase 1/2 Active not recruiting
NCT05074810 2026-01-12
RAMP203
Verastem, Inc.
Phase 1/2 Active not recruiting
NCT05313009 2025-12-16
Tarlox and Sotorasib in Patients With KRAS G12C Mutations
Medical University of South Carolina
Phase 1/2 Terminated
NCT04892017 2025-10-10
A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1/2 Active not recruiting
NCT04720976 2025-04-11
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Allist Pharmaceuticals, Inc.
Phase 1/2 Completed